The risks of risk scores for stroke risk assessment in atrial fibrillation

Editorial on Olesen and Torp-Pedersen. Thromb Haemost 2015; 113: 1165-1169.

• References

• 1 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
• 2 Skjøth F. et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis. Thromb Haemost 2014; 111: 1-8.
• 3 Olesen JB, Torp-Pedersen C. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc β 1, or higher?. Thromb Haemost. 2015. Epub ahead of print
• 4 Lip GYH. et al. Atrial fibrillation patients categorized as ‘not for anticoagulation’ according to the 2014 canadian cardiovascular society algorithm are not ‘low risk’. Can J Cardiol 2015; 31: 24-28.
• 5 Nielsen PB. et al. Using the CHA2DS2-VASc score for stroke prevention in atrial fibrillation: A focus on vascular disease, females and simple practical application. Can J Cardiol. 2015. Epub ahead of print
• 6 Friberg L. et al. Benefit of Anticoagulation Unlikely in Patients With Atrial Fibrillation and a CHA2DS2-VASc Score of 1. J Am Coll Cardiol 2015; 65: 225-232.
• 7 Andersen PK, Keiding N. Interpretability and importance of functionals in competing risks and multistate models. Stat Med 2012; 31: 1074-1088.
• 8 Lip GYH. et al. The value of the European society of cardiology guidelines for refining stroke risk stratification in patients with atrial fibrillation categorized as low risk using the anticoagulation and risk factors in atrial fibrillation stroke score: a nationwide co. Chest 2014; 146: 1337-1346.
• 9 Lip GYH. et al. Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With None or One Stroke Risk Factor(s) based on the CHA2DS2-VASc score. J Am Coll Cardiol. 2015. Epub ahead of print
• 10 Go AS. et al. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med 1999; 131: 927-934.
• 11 Friberg J. et al. Rising rates of hospital admissions for atrial fibrillation. Epidemiology 2003; 14: 666-672.
• 12 Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: Report from the Stockholm Cohort Study of Atrial Fibrillation. Europace 2011; 13: 626-633.
• 13 Rothman KJ. et al. Modern Epidemiology. 3rd ed. Lippincott Williams & Wilkins; 2008
• 14 Andersen PK. et al. Competing risks in epidemiology: possibilities and pitfalls. Int J Epidemiol 2012; 41: 861-870.
• 15 Koller MT. et al. Competing risks and the clinical community: Irrelevance or ignorance?. Stat Med 2012; 31: 1089-1097.
• 16 Fang MC. et al. Trends in stroke rates, risk, and outcomes in the United States, 1988 to 2008. Am. J. Med 2014; pp. 608-615.
• 17 Lip GYH. Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: A commentary. J Thromb Haemost 2013; 11: 615-626.
• 18 Olesen JB. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: a nationwide cohort study. Thromb Haemost 2012; 107: 1172-1179.
• 19 Potpara TS. et al. Reliable identification of ‘truly low’ thromboembolic risk in patients initially diagnosed with ‘lone’ atrial fibrillation the belgrade atrial fibrillation study. Circ Arrhythmia Electrophysiol 2012; 05: 319-326.
• 20 Singer DE, Ezekowitz MD. Adding Rigor to Stroke Risk Prediction in Atrial Fibrillation. J Am Coll Cardiol 2015; 65: 233-235.
• 21 Olesen JB. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
• 22 Friberg L. et al. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. Circulation 2012; 125: 2298-2307.
• 23 Lahaye S. et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2013; 111: 465-473.
• 24 Lane DA, Lip GYH. Patient’s values and p References for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111: 381-383.
• 25 Olesen JB. et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. Br Med J 2011; 342: d124.
• 26 Singer DE. et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: The ATRIA study stroke risk score. J Am Heart Assoc 2013; 02: e000250.
• 27 Taillandier S. et al. Prognosis in patients with atrial fibrillation and CHA 2DS 2-VASc Score = 0 in a community-based cohort study. J Cardiovasc Electrophysiol 2012; 23: 708-713.
• 28 Huang D. et al. Refinement of Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA2 DS2 -VASc Score of 1. Pacing Clin Electrophysiol 2014; 37: 1442-1447.
• 29 Chao T-F. et al. Using the CHA2DS2-VASc Score for Refining Stroke Risk Stratification in ‘Low-Risk’ Asian Patients With Atrial Fibrillation. J Am Coll Cardiol 2014; 64: 1658-1665.
• 30 Chao TF. et al. Should Atrial Fibrillation Patients With One Additional Risk Factor of the CHA2DS2-VASc Score (Beyond Sex) Receive Oral Anticoagulation?. J Am Coll Cardiol 2015; 65: 635-642.
• 31 Olesen JB. Torp-Pedersen C. Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc β1, or higher?. Thromb Haemost 2015; 113: 1165-1169.